Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies

Pathogenic Mechanisms Shared between Psoriasis and Cardiovascular Disease

(2012) Ramin Ghazizadeh et al.   International Journal of Medical Sciences

Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents

(2010) Wolfgang Weger   BRITISH JOURNAL OF PHARMACOLOGY

Psoriasis and Systemic Inflammatory Diseases: Potential Mechanistic Links between Skin Disease and Co-Morbid Conditions

(2010) Batya B. Davidovici et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis

(2010) Christopher E.M. Griffiths et al.   NEW ENGLAND JOURNAL OF MEDICINE

Heart Disease and Stroke Statistics—2010 Update

(2009) et al.   CIRCULATION

Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?

(2009) Eihab A. Alwawi et al.   Dermatologic Therapy

Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database

(2009) N. N. Mehta et al.   EUROPEAN HEART JOURNAL

Cardiovascular disease and classic cardiovascular risk factors in patients with psoriasis

(2009) Alexa Boer Kimball et al.   INTERNATIONAL JOURNAL OF DERMATOLOGY

The Risk of Stroke in Patients with Psoriasis

(2009) Joel M. Gelfand et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Psoriasis May Not be an Independent Risk Factor for Acute Ischemic Heart Disease Hospitalizations: Results of a Large Population-Based Dutch Cohort

(2009) Marlies Wakkee et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Psoriasis is independently associated with psychiatric morbidity and adverse cardiovascular risk factors, but not with cardiovascular events in a population-based sample

(2009) J Schmitt et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial

(2009) Alice Gottlieb et al.   LANCET

Safety and Efficacy of ABT-874, a Fully Human Interleukin 12/23 Monoclonal Antibody, in the Treatment of Moderate to Severe Chronic Plaque Psoriasis

(2008) Alexa B. Kimball   ARCHIVES OF DERMATOLOGY

The balance between pro- and anti-inflammatory cytokines is associated with platelet aggregability in acute coronary syndrome patients

(2008) A.M. Gori et al.   ATHEROSCLEROSIS

Exact and efficient inference procedure for meta-analysis and its application to the analysis of independent 2 x 2 tables with all available data but without artificial continuity correction

(2008) L. Tian et al.   BIOSTATISTICS

The psychosocial and occupational impact of chronic skin disease

(2008) Judith Hong et al.   Dermatologic Therapy

A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease

(2008) William J. Sandborn et al.   GASTROENTEROLOGY

National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening

(2008) Alexa B. Kimball et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

(2008) Craig L Leonardi et al.   LANCET

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

(2008) Kim A Papp et al.   LANCET

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

(2008) Benjamin M Segal et al.   LANCET NEUROLOGY